Skip to main content
SpringerLink
Log in

Gemcitabine

  • Chapter
Extravasation of Cytotoxic Agents

Abstract

1. Stop injection/infusion immediately

2. Get extravasation kit

3. Put on (sterile) gloves

4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Original articles

  1. Aapro MS, Martin C, Hatty S: Gemcitabine – a safety review. Anti-Cancer Drugs 9: 191–201, 1998.

    Article  PubMed  CAS  Google Scholar 

  2. Langstein HN, Duman H, Seelig D, et al: Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 49: 369–374, 2002.

    Article  PubMed  Google Scholar 

  3. Krämer I: Zehn Jahre Dokumentation von Zytostatika-Paravasat-Ereignissen: Auswertung von 175 Paravasate-Dokumentationen. Krankenhauspharmazie 23: 269–274, 2002.

    Google Scholar 

Secondary literature

  1. Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.

    Google Scholar 

  2. van Gemmern R: Gewebstoxizität und Paravasatbehandlung -neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.

    Google Scholar 

  3. Eli Lilly, peronal communication, April 2005.

    Google Scholar 

  4. Berdel WE, Schmoll HJ, Büchele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, vol 1, 3rd edition: 1689–1701, 1999.

    Google Scholar 

  5. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.

    Google Scholar 

  6. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  7. Barth J: Paravasate und deren Behandlung. In: Barth J (ed) Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.

    Google Scholar 

  8. Gain M, Melzer S, Meyer-Jürshof A, et al: Gemcitabin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 5: 37–38, 2001.

    Google Scholar 

  9. Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.

    Article  PubMed  CAS  Google Scholar 

  10. Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.

    Article  PubMed  CAS  Google Scholar 

  11. Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CRETA – Cancer Research & Trial Agency GmbH, Bad Sauerbrunn, Österreich

    Ines Mader MD

  2. Krankenhaus und Geriatriezentrum, SMZ Floridsdorf, Wien, Österreich

    Mag. pharm. Patrizia Fürst-Weger

  3. Klinische Abteilung für Onkologie, Univ.-Klinik für Innere Medizin I, Wien, Österreich

    Univ.-Prof. Dr. Robert Mader

  4. Anstaltsapotheke, Landeskrankenhaus – Universitätskliniken Innsbruck, Innsbruck, Österreich

    Mag. pharm. Dr. Elisabeth Nogler-Semenitz

  5. Apotheke LKH-Univ.-Klinikum Graz, Graz, Österreich

    Mag. pharm. Sabine Wassertheurer

Authors
  1. Ines Mader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mag. pharm. Patrizia Fürst-Weger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Univ.-Prof. Dr. Robert Mader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mag. pharm. Dr. Elisabeth Nogler-Semenitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mag. pharm. Sabine Wassertheurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Gemcitabine. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-88893-3_38

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-88889-6

  • Online ISBN: 978-3-211-88893-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation